These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8339466)

  • 1. Do angiotensin converting enzyme inhibitors limit myocardial infarct size?
    Miki T; Miura T; Shimamoto K; Urabe K; Sakamoto J; Iimura O
    Clin Exp Pharmacol Physiol; 1993 Jun; 20(6):429-34. PubMed ID: 8339466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.
    Hartman JC; Wall TM; Hullinger TG; Shebuski RJ
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):996-1003. PubMed ID: 7687728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC
    Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
    Wolfrum S; Richardt G; Dominiak P; Katus HA; Dendorfer A
    Br J Pharmacol; 2001 Sep; 134(2):370-4. PubMed ID: 11564655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.
    Black SC; Driscoll EM; Lucchesi BR
    Pharmacology; 1998 Jul; 57(1):35-46. PubMed ID: 9670211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.
    Hartman JC; Hullinger TG; Wall TM; Shebuski RJ
    Eur J Pharmacol; 1993 Apr; 234(2-3):229-36. PubMed ID: 8482328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
    Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
    Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.
    Martorana PA; Schölkens BA
    Agents Actions Suppl; 1992; 38 ( Pt 3)():98-102. PubMed ID: 1462888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
    Ehring T; Baumgart D; Krajcar M; Hümmelgen M; Kompa S; Heusch G
    Circulation; 1994 Sep; 90(3):1368-85. PubMed ID: 8087948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation.
    Miki T; Miura T; Ura N; Ogawa T; Suzuki K; Shimamoto K; Iimura O
    J Am Coll Cardiol; 1996 Nov; 28(6):1616-22. PubMed ID: 8917279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size.
    Parlakpinar H; Ozer MK; Acet A
    Cytokine; 2011 Dec; 56(3):688-94. PubMed ID: 21975128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.
    Schriefer JA; Broudy EP; Hassen AH
    J Pharmacol Exp Ther; 2001 Sep; 298(3):970-5. PubMed ID: 11504792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.
    Tomoda F; Lew RA; Smith AI; Madden AC; Evans RG
    Br J Pharmacol; 1996 Sep; 119(2):365-73. PubMed ID: 8886422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of renal hemodynamic effect of ramiprilat to captopril; possible role of kinins.
    Chen K; Zimmerman BG
    J Pharmacol Exp Ther; 1994 Aug; 270(2):491-7. PubMed ID: 8071842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts.
    Mital S; Loke KE; Slater JP; Addonizio L; Gersony WM; Hintze TH
    Am J Cardiol; 1999 Jun; 83(12A):92H-98H. PubMed ID: 10750596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism.
    Wall TM; Linseman DA; Hartman JC
    Eur J Pharmacol; 1996 Jun; 306(1-3):165-74. PubMed ID: 8813629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reduction of infarct size and remodeling after ramipril].
    Martorana PA; Linz W; Schölkens BA
    Z Kardiol; 1994; 83 Suppl 4():63-4. PubMed ID: 7856282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Converting enzyme inhibitor-stimulated formation of nitric oxide and prostacyclin in endothelial cells from bovine aorta is mediated by endothelium-derived bradykinin.
    Wiemer G; Schölkens BA; Becker RH
    Agents Actions Suppl; 1992; 38 ( Pt 3)():196-200. PubMed ID: 1334350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat.
    Hartman JC; Kurc GM; Hullinger TG; Wall TM; Sheehy RM; Shebuski RJ
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1071-6. PubMed ID: 7523655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies on differential inhibition of the renin - angiotensin system in the anesthetized guinea pig.
    Duan J; Jaramillo J; Jung GL; McLeod AL; Fernandes BH; Mathis D
    Can J Physiol Pharmacol; 1995 Oct; 73(10):1512-8. PubMed ID: 8748944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.